We are studying a new treatment combination for patients with metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck, or metastatic urothelial bladder cancer. The goal is to evaluate its effectiveness and safety as a first-line therapy.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) is a type of cancer that starts in the squamous cells of the head and neck and has spread to other parts of the body, often causing symptoms like difficulty swallowing, persistent sore throat, and changes in voice.
Metastatic Urothelial Bladder Cancer (mUBC) is a form of bladder cancer that has spread beyond the bladder to other parts of the body, leading to symptoms such as blood in urine, frequent urination, and pelvic pain.
Metastatic Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer that has spread to other areas of the body, often causing symptoms like persistent cough, chest pain, and shortness of breath.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.